151
Participants
Start Date
January 11, 2017
Primary Completion Date
July 31, 2019
Study Completion Date
December 29, 2021
Lenvatinib
Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
Placebo
Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
1002 Eisai Trial Site, Beijing
1006 Eisai Trial Site, Beijing
1020 Eisai Trial Site, Beijing
1026 Eisai Trial Site, Beijing
1025 Eisai Trial Site, Xiamen
1012 Eisai Trial Site, Lanzhou
1003 Eisai Trial Site, Guangzhou
1027 Eisai Trial Site, Guilin
1018 Eisai Trial Site, Zhengzhou
1023 Eisai Trial Site, Wuhan
1016 Eisai Trial Site, Changsha
1021 Eisai Trial Site, Changsha
1008 Eisai Trial Site, Nanjing
1014 Eisai Trial Site, Nanjing
1022 Eisai Trial Site, Changchun
1015 Eisai Trial Site, Shenyang
1004 Eisai Trial Site, Shanghai
1017 Eisai Trial Site, Shanghai
1019 Eisai Trial Site, Shanghai
1011 Eisai Trial Site, Taiyuan
1007 Eisai Trial Site, Chengdu
1001 Eisai Trial Site, Tianjin
1010 Eisai Trial Site, Tianjin
1005 Eisai Trial Site, Hangzhou
Eisai Co., Ltd.
INDUSTRY